Investigating Cardiac Morphological Alterations in a Pentylenetetrazol-Kindling Model of Epilepsy


Creative Commons License

Akyuz E., Polat K., ATEŞ Ş., Unalmis D., TOKPINAR A., YILMAZ S., ...Daha Fazla

DIAGNOSTICS, cilt.10, sa.6, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10 Sayı: 6
  • Basım Tarihi: 2020
  • Doi Numarası: 10.3390/diagnostics10060388
  • Dergi Adı: DIAGNOSTICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: SUDEP, epilepsy, pentylenetetrazol, heart, electrocardiographic recordings, SUDDEN UNEXPECTED DEATH, DYSFUNCTION, MECHANISMS
  • Yozgat Bozok Üniversitesi Adresli: Evet

Özet

Epilepsy is a group of neurological disorders characterized by abnormal electrical activity in the central nervous system (CNS) and recurrent seizures representing the principal clinical manifestation. Sudden unexpected death in epilepsy (SUDEP) is the predominant cause of death in young epileptic patients. SUDEP patients displayed an increased cardiovascular (CV) risk, probably due to an impaired autonomic control of CV functions, but the underlying mechanisms need to be explored yet. Therefore, we aimed to examine the cardiac morphological alterations in a pentylenetetrazol (PTZ)-kindled rat model, a well-established tool for studying chronic epilepsy. To complete this, the distance between the atria, between the atrium and ventricle were measured, the heart was weighed, and the pathological morphology of dissected hearts was analyzed by histological assessment with hematoxylin and eosin staining. A significantly decreased distance between atria and a significant increase in heart weight were observed in PTZ-kindled rats which interestingly also displayed increased hemorrhagic content when compared with controls. Our findings provided evidence that changes in cardiac morphology may be related to autonomic CV dysfunctions occurring during SUDEP while also opening up more avenues to better develop novel drugs for the treatment of this disorder.